This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bruker (BRKR) Updates 2021 Outlook, Issues Medium-Term View
by Zacks Equity Research
Bruker (BRKR) updates 2021 financial guidance encouraged by solid business growth and high-growth opportunities.
Walgreens' (WBA) Retail Products Now Available on Uber Eats
by Zacks Equity Research
Walgreens (WBA) now offers on-demand product delivery through an expanded collaboration with Uber.
Phirbo (PAHC) Nutritional Specialties Grow, Vaccine Sales Dip
by Zacks Equity Research
Currently, Phirbo (PAHC) is focused on expanding its footprint in the poultry, swine and cattle industries, in both domestic and international markets.
ResMed (RMD) Rallies as Philips Falters on Mass Product Recall
by Zacks Equity Research
The full U.S. launch of ResMed (RMD) AirSense 11 is expected any time in 2021, which might receive bigger market acceptance capitalizing on its current peer position.
Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) on strong growth in CAG business and bullish 2021 outlook.
LabCorp (LH) Boosts Precision Oncology With INSIGHT NGS Launch
by Zacks Equity Research
LabCorp (LH) enables evidence-based, personalized treatment suggestions based on the genomic profiling of a patient's solid tumor with the launch of new test.
Medtronic (MDT) Progresses in SCS With FDA Nod for Vanta
by Zacks Equity Research
Vanta utilizes Medtronic's (MDT) proprietary AdaptiveStim technology for personalized pain relief.
Teleflex (TFX) Procedure Volume Recovers as Pandemic Subsides
by Zacks Equity Research
The UroLift System remains a major contributor to Teleflex (TFX) revenues.
Edwards Lifesciences (EW) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on its promising Surgical Structural Heart business and bullish 2021 guidance.
Henry Schein (HSIC) Enhances Dental Practices With New Deal
by Zacks Equity Research
Henry Schein's (HSIC) acquisition of majority stake in eAssist will enable it to offer best quality solutions to help dental practices operate efficiently and profitably.
Tandem (TNDM) Presents Data Backing Control-IQ Technology
by Zacks Equity Research
Data presented at the ATTD conference demonstrates Tandem Diabetes Care's (TNDM) Control-IQ technology's ability to make a positive and sustained impact on diabetes care.
Hologic (HOLX) Acessa Procedure Now Covered by Cigna Insurance
by Zacks Equity Research
Hologic's (HOLX) Acessa procedure new coverage will further validate Laparoscopic Radiofrequency Ablation as a standard of care for uterine fibroids.
LabCorp's (LH) Pixel Home Collection Kit Now in WBA Stores
by Zacks Equity Research
According to LabCorp (LH), the on-demand delivery option is useful for individuals showing symptoms of COVID-19 infection who want to be tested without potentially infecting others.
CVS Health (CVS) Deploys Time-Delay Safes in Georgia Pharmacies
by Zacks Equity Research
CVS Health's (CVS) time-delay safes are anticipated to help reduce robbery incidents.
Thermo Fisher (TMO) End Markets Rebound as COVID-19 Cases Drop
by Zacks Equity Research
In academic and government end markets, Thermo Fisher (TMO) grows on robust customer activity globally.
Medtronic (MDT) Progresses in Neuromodulation on New FDA Nod
by Zacks Equity Research
Medtronic's (MDT) SenSight claims to deliver patient-specific DBS therapy for the treatment of symptoms associated with Parkinson's, dystonia and essential tremor and medically refractory epilepsy.
Abbott (ABT) Confirms Capacity to Support MCS Devices Demand
by Zacks Equity Research
Abbott's (ABT) HeartMate 3 heart pump can significantly enhance quality of life and reduce adverse events.
Here's Why You Should Retain CVS Health (CVS) in Your Portfolio
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) on solid first-quarter performance and growth in digital health services.
Idexx Laboratories (IDXX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Idexx Laboratories (IDXX) closed the most recent trading day at $560.35, moving +0.36% from the previous trading session.
STERIS (STE) Expands Product Suite With New Acquisition
by Zacks Equity Research
STERIS' (STE) acquisition of Cantel Medical will complement and broaden the former's product and service offerings, global reach and customers.
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (IDXX) Outperforming Other Medical Stocks This Year?
IDEXX (IDXX) Acquires ezyVet to Boost Practice Management Arm
by Zacks Equity Research
The latest acquisition adds to IDEXX's (IDXX) cloud-based practice information management system (PIMS) segment.
Why Is Idexx (IDXX) Up 3.3% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why IDEXX (IDXX) Could Be an Impressive Growth Stock
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider IDEXX (IDXX).
Henry Schein (HSIC) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Henry Schein (HSIC) is optimistic about maintaining robust sales of PPE and COVID-19-related products.